-
Two Studies of Dr. Yong Xu’s Teamat the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies
The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year’s EAU Congress, Dr. Yong Xu’s team…
-
Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023
The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology…
-
Two renal cancer-related studies by Dr. KanGong ‘s team selected for the 2023 EAU Annual Meeting
The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world’s fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two…
-
Dr. HuiqiangHuang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.
Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt,…
-
Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia
T-cell lymphoblastic lymphoma (T-LBL) is a highly malignant and rare lymphoma with aggressive behavior. It primarily affects adolescents, often presenting with mediastinal lymph node enlargement and commonly accompanied by pericardial and pleural effusions. In some cases, the disease can involve the central nervous system (CNS) with neurological manifestations. About 20% of patients progress to acute…
-
Dr. QianJiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients
From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian’s team from Peking University People’s Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the…
-
Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases at 2023 EHA
The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children’s Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of research,…
-
Dr. Liu Hongxing and Wang Tong: Decoding Structural Aberrations of the PAX5 Gene in B-ALL and its Correlation with Diagnostic Classification and Treatment Outcomes
Acute B lymphoblastic leukemia (B-ALL) is a clonal heterogeneous disease caused by mutations in genes associated with the development and proliferation of B lymphocytes, which obstructs the normal differentiation and maturation of B lymphocyte progenitor cells. Although the complete remission rate for adult ALL patients can exceed 80% after induction remission therapy, most patients eventually…
Connecting Medical Expertise through Media